Saniona AB has selected SAN-2668 as a first-in-class clinical candidate for pediatric epilepsy.

Jazz Pharmaceuticals plc and Saniona AB have entered into a global license agreement for Jazz to obtain exclusive worldwide rights to develop and commercialize SAN-2355 for epilepsy and other potential indications.

Saniona AB has initiated preclinical development of SAN-2355, a potential best-in-class and new-generation Kv7.2/Kv7.3 activator for the treatment of focal onset seizures.

Saniona AB has selected its proprietary GABA-A α5 negative allosteric modulator lead compound, SAN-2465, as a clinical candidate for major depressive disorder following encouraging results in a rodent model.

Saniona AB has reported that it has selected SAN-2355 as the first clinical candidate from its Kv7 epilepsy program and is poised to advance it into preclinical development.

Saniona AB has established a new research collaboration with Astronautx Ltd. in Alzheimer’s disease. The aim of the collaboration is to identify new treatments for Alzheimer’s disease and other neurodegenerative conditions by modulating a novel, undisclosed ion channel target. The research collaboration will use Saniona’s proprietary platform, Ionbase, for the modulation of ion channels.

Saniona AB has completed preclinical development with SAN-903 and is ready to start the regulatory process for entering phase I trials either alone or together with a partner. SAN-903 is a novel, potential first-in-class medicine based on inhibition of the calcium-activated potassium ion channel KCa3.1.